As we continue preparing to meet with investors, strategic partners and companies in 2018, we have successfully completed a fifth preclinical study to evaluate our surgical navigation system, IOPS.

This study was our most noteworthy to-date, as we demonstrated the ability to track sensorized IOPS instruments precisely and efficiently, with enhanced 3D visualization, and without the frequent exposure to cancer-causing ionizing radiation associated with current standard of care.

The study was led by Dr. Matthew Eagleton, Chief of Massachusetts General Hospital’s Division of Vascular and Endovascular Surgery and co-director of the Fireman Vascular Center and Thoracic Aorta Center, and Dr. Ezequiel Parodi, vascular surgeon and endovascular specialist at Cleveland Clinic’s Miller Heart & Vascular Institute and Scientific Advisor to Centerline. “I observed a high level view of vasculature along with a more magnified, localized view,” Dr. Parodi, a first-time user of IOPS, noted. “I don’t have to constantly change views to highlight areas of interest.”

Dr. Eagleton took note of the device’s progress and ease of adoption, stating, “I am impressed by the rapid advancement of Centerline’s platform technology as evidenced by the results of this preclinical study. I see surgeons and administrators being able to quickly adapt this technology within their own facilities.”
With another successful, noteworthy preclinical study under our belt, the New Year is already in full swing at Centerline Biomedical. We look forward to continue making strides toward our goal of medical device market entry!